| Year |
Citation |
Score |
| 2023 |
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, et al. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 77: S305-S313. PMID 37843118 DOI: 10.1093/cid/ciad547 |
0.347 |
|
| 2023 |
Doernberg SB, Arias CA, Altman DR, Babiker A, Boucher HW, Creech CB, Cosgrove SE, Evans SR, Fowler VG, Fritz SA, Hamasaki T, Kelly BJ, Leal SM, Liu C, Lodise TP, et al. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 77: S295-S304. PMID 37843115 DOI: 10.1093/cid/ciad565 |
0.329 |
|
| 2023 |
Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Annals of Intensive Care. 13: 52. PMID 37322293 DOI: 10.1186/s13613-023-01146-5 |
0.399 |
|
| 2023 |
Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Journal of Managed Care & Specialty Pharmacy. 1-13. PMID 37307087 DOI: 10.18553/jmcp.2023.22454 |
0.337 |
|
| 2022 |
Lodise TP, Chopra T, Nathanson BH, Sulham K, Rodriguez M. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases. 9: ofac315. PMID 35899279 DOI: 10.1093/ofid/ofac315 |
0.327 |
|
| 2022 |
O'Donnell JN, Lodise TP. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. Antimicrobial Agents and Chemotherapy. 66: e0025622. PMID 35727059 DOI: 10.1128/aac.00256-22 |
0.309 |
|
| 2022 |
Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V, Holland TL. Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Bloodstream Infections. Open Forum Infectious Diseases. 9: ofab651. PMID 35079599 DOI: 10.1093/ofid/ofab651 |
0.304 |
|
| 2021 |
Lodise T, Rodriguez M, Chitra S, Wright K, Patel N. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. Antibiotics (Basel, Switzerland). 10. PMID 34680776 DOI: 10.3390/antibiotics10101195 |
0.589 |
|
| 2021 |
Lodise TP, Henriksen AS, Hadley T, Patel N. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infectious Diseases. 8: ofab380. PMID 34660834 DOI: 10.1093/ofid/ofab380 |
0.513 |
|
| 2021 |
O'Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options? Pharmacotherapy. PMID 34170571 DOI: 10.1002/phar.2607 |
0.343 |
|
| 2021 |
O'Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options? Pharmacotherapy. PMID 34170571 DOI: 10.1002/phar.2607 |
0.343 |
|
| 2021 |
Lodise TP, Drusano G. Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients First. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33740042 DOI: 10.1093/cid/ciaa1744 |
0.379 |
|
| 2021 |
Lodise TP, Mistry R, Young K, LaPensee K. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection. Clinical Drug Investigation. PMID 33604769 DOI: 10.1007/s40261-021-01005-w |
0.349 |
|
| 2021 |
Patel N, Lowry C, Morgenson D, Shah V, Stornelli N, Lodise TP. Comparative Effectiveness of Early-Targeted Use of Fidaxomicin versus Oral Vancomycin among Hospitalized Veterans' Affairs Patients with Infections due to Clostridioides difficile. Pharmacotherapy. PMID 33455007 DOI: 10.1002/phar.2503 |
0.593 |
|
| 2021 |
LaPensee K, Lodise T. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. American Health & Drug Benefits. 11: 449-459. PMID 30746017 |
0.31 |
|
| 2020 |
Ferry T, Lodise TP, Gallagher JC, Forestier E, Goutelle S, Tam VH, Mohr JF, Roubaud-Baudron C. Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Frontiers in Medicine. 7: 585658. PMID 33425938 DOI: 10.3389/fmed.2020.585658 |
0.331 |
|
| 2020 |
Lodise TP, Van Wart S, Sund ZM, Bressler AM, Khan A, Makley AT, Hamad Y, Salata RA, Silveira FP, Sims MD, Kabchi BA, Saad MA, Brown C, Oler RE, Fowler V, et al. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multi-Center Study (ACUMIN). Antimicrobial Agents and Chemotherapy. PMID 33168615 DOI: 10.1128/AAC.01809-20 |
0.318 |
|
| 2020 |
Lodise TP, Kanakamedala H, Hsu WC, Cai B. Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters". Pharmacotherapy. 40: 889-901. PMID 33112456 DOI: 10.1002/Phar.2446 |
0.48 |
|
| 2020 |
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. The Lancet. Infectious Diseases. PMID 33058795 DOI: 10.1016/S1473-3099(20)30796-9 |
0.3 |
|
| 2020 |
Yasmin M, Hanrahan J, Marshall S, Lodise TP, Chen L, Perez F, Kreiswirth B, Bonomo RA. Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam. Open Forum Infectious Diseases. 7: ofaa349. PMID 32964066 DOI: 10.1093/Ofid/Ofaa349 |
0.387 |
|
| 2020 |
Lodise TP, Van Le H, LaPensee K. Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals. Antibiotics (Basel, Switzerland). 9. PMID 32899697 DOI: 10.3390/Antibiotics9090577 |
0.417 |
|
| 2020 |
Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infectious Diseases and Therapy. PMID 32740858 DOI: 10.1007/S40121-020-00325-2 |
0.307 |
|
| 2020 |
Patel N, Stornelli N, Sangiovanni RJ, Huang DB, Lodise TP. Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions Among Hospitalized Veterans' Affairs Patients with Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy. PMID 32718970 DOI: 10.1128/Aac.01268-20 |
0.604 |
|
| 2020 |
Alosaimy S, Murray KP, Zasowski EJ, Morrisette T, Lagnf AM, Lodise TP, Rybak MJ. Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32716506 DOI: 10.1093/Cid/Ciaa1039 |
0.435 |
|
| 2020 |
O'Donnell JN, Bidell MR, Lodise TP. Approach to the treatment of patients with serious multidrug-resistant Pseudomonas aeruginosa infections. Pharmacotherapy. PMID 32696452 DOI: 10.1002/Phar.2449 |
0.422 |
|
| 2020 |
Lodise TP, Izmailyan S, Olesky M, Lawrence K. An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed? Open Forum Infectious Diseases. 7: ofaa237. PMID 32676511 DOI: 10.1093/Ofid/Ofaa237 |
0.407 |
|
| 2020 |
Rybak MJ, Le J, Lodise T, Levine D, Bradley J, Liu C, Mueller B, Pai M, Wong-Beringer A, Rotschafer JC, Rodvold K, Maples HD, Lomaestro BM. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Journal of the Pediatric Infectious Diseases Society. 9: 281-284. PMID 32659787 DOI: 10.1093/Jpids/Piaa057 |
0.306 |
|
| 2020 |
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32658968 DOI: 10.1093/Cid/Ciaa303 |
0.38 |
|
| 2020 |
Lodise TP, Tillotson GS, Spargo A, Bozkaya D, Massey J. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model. Clinical Drug Investigation. PMID 32651832 DOI: 10.1007/S40261-020-00938-Y |
0.372 |
|
| 2020 |
Lodise TP, Colman S, Alexander E, Stein DS, Fitts D, Goldberg L, Schranz J. Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. Open Forum Infectious Diseases. 7: ofaa209. PMID 32617376 DOI: 10.1093/Ofid/Ofaa209 |
0.322 |
|
| 2020 |
Mercuro NJ, Lodise TP, Kenney RM, Rezik B, Vemulapalli RC, Costandi MJ, Davis SL. Impact of unit-specific metrics and prescribing tools on a family medicine ward. Infection Control and Hospital Epidemiology. 1-7. PMID 32605686 DOI: 10.1017/Ice.2020.288 |
0.35 |
|
| 2020 |
Estrada S, Lodise TP, Tillotson GS, Delaportas D. The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies. Drugs - Real World Outcomes. 7: 6-12. PMID 32588389 DOI: 10.1007/S40801-020-00199-3 |
0.434 |
|
| 2020 |
Whittaker C, Lodise TP, Nhan E, Reilly J. Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway. Drugs - Real World Outcomes. PMID 32588388 DOI: 10.1007/S40801-020-00196-6 |
0.42 |
|
| 2020 |
Helton B, MacWhinnie A, Minor SB, Lodise TP, Rafferty KD, Allison SL. Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis. Drugs - Real World Outcomes. PMID 32588384 DOI: 10.1007/S40801-020-00201-Y |
0.387 |
|
| 2020 |
Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, Zhou J, Tao X, Bulitta JB, Fowler VG, Chambers HF, Bonomo RA, Tsuji BT. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. The Journal of Antimicrobial Chemotherapy. PMID 32464664 DOI: 10.1093/Jac/Dkaa197 |
0.334 |
|
| 2020 |
Lodise T, Colman S, Stein DS, Fitts D, Goldberg L, Alexander E, Scoble PJ, Schranz J. Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. Open Forum Infectious Diseases. 7: ofaa145. PMID 32462049 DOI: 10.1093/Ofid/Ofaa145 |
0.343 |
|
| 2020 |
Lodise TP, Rybak MJ. COVID-19: Important Therapy Considerations and Approaches in this Hour of Need. Pharmacotherapy. PMID 32267556 DOI: 10.1002/Phar.2396 |
0.363 |
|
| 2020 |
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. PMID 32227354 DOI: 10.1002/Phar.2376 |
0.359 |
|
| 2020 |
Noviello S, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM, Dryden M, Balser B, Scaramucci A, Torres A, Huang DB. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. Journal of Medical Microbiology. PMID 32195649 DOI: 10.1093/Ofid/Ofy210.1170 |
0.439 |
|
| 2020 |
Tillotson G, Lodise T, Classi P, Mildvan D, McKinnell JA. Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study. Open Forum Infectious Diseases. 7: ofaa065. PMID 32195289 DOI: 10.1093/Ofid/Ofaa065 |
0.395 |
|
| 2020 |
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. PMID 32191793 DOI: 10.1093/Ajhp/Zxaa036 |
0.306 |
|
| 2020 |
Maskarinec SA, Park LP, Ruffin F, Turner NA, Patel N, Eichenberger EM, van Duin D, Lodise T, Fowler VG, Thaden JT. Positive follow-up blood cultures identify high mortality risk Among patients with gram negative bacteremia. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 32114010 DOI: 10.1016/J.Cmi.2020.01.025 |
0.557 |
|
| 2020 |
Kullar R, Puzniak LA, Swindle JP, Lodise T. Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting. Infectious Diseases and Therapy. PMID 31974828 DOI: 10.1007/S40121-019-00279-0 |
0.385 |
|
| 2020 |
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Corrigendum to: Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection. Open Forum Infectious Diseases. 7: ofz536. PMID 31951222 DOI: 10.1093/Ofid/Ofz536 |
0.331 |
|
| 2020 |
Lodise T, LaPensee K. Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models. American Health & Drug Benefits. 12: 168-176. PMID 31428234 |
0.305 |
|
| 2020 |
Lodise T, Tillotson GS. Managing Bacterial Infections in the Era of COVID-19 Infectious Diseases in Clinical Practice. 28: 251-254. DOI: 10.1097/Ipc.0000000000000894 |
0.322 |
|
| 2019 |
Lodise TP, Palazzolo C, Reksc K, Packnett E, Redell M. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting. Open Forum Infectious Diseases. 6: ofz475. PMID 31844636 DOI: 10.1093/Ofid/Ofz475 |
0.405 |
|
| 2019 |
Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, D'Souza R, Lodise TP, Rhoads DD, Hujer AM, Rojas LJ, Hoyen C, Perez F, Edwards A, Bonomo RA. Monitoring Ceftazidime-Avibactam (CAZ-AVI) and Aztreonam (ATM) Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying both KPC-4 and NDM-1 Carbapenemases. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31802119 DOI: 10.1093/Cid/Ciz1155 |
0.37 |
|
| 2019 |
Lodise TP, Bonine NG, Ye JM, Folse HJ, Gillard P. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections. Bmc Infectious Diseases. 19: 718. PMID 31412809 DOI: 10.1186/S12879-019-4363-Y |
0.439 |
|
| 2019 |
Lodise TP, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Bonine NG. Antimicrobial Resistance or Delayed Appropriate Therapy-Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae? Open Forum Infectious Diseases. 6: ofz194. PMID 31198817 DOI: 10.1093/Ofid/Ofz194 |
0.435 |
|
| 2019 |
Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, et al. The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31157370 DOI: 10.1093/Cid/Ciz460 |
0.446 |
|
| 2019 |
Rizk ML, Bhavnani SM, Drusano G, Dane A, Eakin AE, Guina T, Jang SH, Tomayko JF, Wang J, Zhuang L, Lodise TP. Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. Antimicrobial Agents and Chemotherapy. PMID 30833427 DOI: 10.1128/Aac.02309-18 |
0.317 |
|
| 2019 |
Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T. Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. The American Journal of the Medical Sciences. 357: 103-110. PMID 30665490 DOI: 10.1016/J.Amjms.2018.11.009 |
0.456 |
|
| 2019 |
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz446 |
0.342 |
|
| 2019 |
Lodise T, Colman S, Alexander E, Stein D, Fitts D, Goldberg L, Schranz J. 676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2) Open Forum Infectious Diseases. 6: S308-S309. DOI: 10.1093/Ofid/Ofz360.744 |
0.338 |
|
| 2019 |
Huang DB, Noviello SS, Lodise T, McKinnell J, Dwyer JP. 439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies Open Forum Infectious Diseases. 6: S218-S218. DOI: 10.1093/Ofid/Ofz360.512 |
0.406 |
|
| 2019 |
Lodise T, Kanakamedala H, Hsu W, Cai B. 216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI) Open Forum Infectious Diseases. 6: S127-S127. DOI: 10.1093/Ofid/Ofz360.291 |
0.418 |
|
| 2019 |
Lodise T, Kanakamedala H, Hsu W, Cai B. 164. Analysis of Adult, Hospitalized Patients With Carbapenem-resistant (CR) Gram-Negative Bloodstream Infections (GN-BSIs) due to Lactose Fermenters (LFs) and Non-lactose Fermenters (NLFs): Is There a Difference in Outcomes? Open Forum Infectious Diseases. 6: S107-S107. DOI: 10.1093/Ofid/Ofz360.239 |
0.41 |
|
| 2019 |
Puzniak L, Gupta V, Dillon RJ, Yu K, Murray J, Lodise T. 2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions? Open Forum Infectious Diseases. 6: S777-S777. DOI: 10.1093/Ofid/Ofz360.1948 |
0.368 |
|
| 2019 |
Lodise T, Izmailyan S, Olesky M, Lawrence K, Tsai L. 2264. An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset (CO) “Low-Risk” (LR) Complicated Intra-Abdominal Infections (cIAI) Across US Hospitals Open Forum Infectious Diseases. 6: S775-S775. DOI: 10.1093/Ofid/Ofz360.1942 |
0.465 |
|
| 2019 |
O’Donnell JN, Alnasser D, Maring BL, Lodise T. 1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA) Open Forum Infectious Diseases. 6: S584-S584. DOI: 10.1093/Ofid/Ofz360.1465 |
0.364 |
|
| 2019 |
Lodise T, Gelone SP, Yu K, Gupta K, Early M, Ye G, Schranz J, Gupta V. 1485. Trends in Important-Resistant Gram-Negative (GN) and Gram-Positive (GP) Urine Bacterial Pathogens in Hospitalized Patients in the United States: A Multicenter Evaluation from 2013 to 2018 Open Forum Infectious Diseases. 6: S541-S541. DOI: 10.1093/Ofid/Ofz360.1349 |
0.425 |
|
| 2019 |
Lodise T, Gupta V, Yu K, Gupta K, Early M, Ye G, Schranz J, Gelone SP. 1440. Prevalence and Regional Variation of in ESBLs and CRE Enterobacteriaceae (ENT) among Adult, Hospitalized Patients with ENT on a Urine Culture: A Multicenter Evaluation Open Forum Infectious Diseases. 6: S525-S526. DOI: 10.1093/Ofid/Ofz360.1304 |
0.395 |
|
| 2019 |
Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d’Aloja E, Locci E, Gilchrist A, Prozialeck W, Rhodes NJ, Lodise T, Fitzgerald J, Downes KJ, Downes KJ, et al. 1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam Open Forum Infectious Diseases. 6: S483-S483. DOI: 10.1093/Ofid/Ofz360.1199 |
0.327 |
|
| 2018 |
Tartof SY, Kuntz JL, Chen LH, Wei R, Puzniak L, Tian Y, Im TM, Takhar HS, Merchant S, Lodise T. Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection. Jama Network Open. 1: e183927. PMID 30646267 DOI: 10.1001/jamanetworkopen.2018.3927 |
0.362 |
|
| 2018 |
Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infectious Diseases. 5: ofy297. PMID 30539040 DOI: 10.1093/Ofid/Ofy297 |
0.356 |
|
| 2018 |
Lodise TP, Zhao Q, Fahrbach K, Gillard PJ, Martin A. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? Bmc Infectious Diseases. 18: 625. PMID 30518337 DOI: 10.1186/S12879-018-3524-8 |
0.41 |
|
| 2018 |
Bland CM, Pai MP, Lodise TP. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Pharmacotherapy. PMID 30403305 DOI: 10.1002/Phar.2193 |
0.453 |
|
| 2018 |
Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infectious Diseases. 5: ofy220. PMID 30349845 DOI: 10.1093/Ofid/Ofy220 |
0.391 |
|
| 2018 |
Bidell MR, Lodise TP. Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings. Pharmacotherapy. PMID 30289995 DOI: 10.1002/Phar.2184 |
0.391 |
|
| 2018 |
Crass RL, Pai MP, Lodise TP. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? The Journal of Antimicrobial Chemotherapy. PMID 30252050 DOI: 10.1093/Jac/Dky388 |
0.343 |
|
| 2018 |
Patel N, Huang D, Lodise T. Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clinical Drug Investigation. PMID 30105549 DOI: 10.1007/S40261-018-0686-5 |
0.592 |
|
| 2018 |
Martin A, Fahrbach K, Zhao Q, Lodise T. Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to : Results of a Systematic Literature Review and Meta-analysis. Open Forum Infectious Diseases. 5: ofy150. PMID 30046639 DOI: 10.1093/Ofid/Ofy150 |
0.44 |
|
| 2018 |
Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM, Dryden M, Balser B, Desplats E, Torres A. A Pooled Analysis of the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Versus Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections. International Journal of Antimicrobial Agents. PMID 29783024 DOI: 10.1016/J.Ijantimicag.2018.05.012 |
0.365 |
|
| 2018 |
Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. A Phase 3,andomized, double-blind, multicenter study toaluate the safety and efficacy of intravenousclaprim versusancomycin for the tratment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens: REVIVE-2. Antimicrobial Agents and Chemotherapy. PMID 29530858 DOI: 10.1128/Aac.02580-17 |
0.389 |
|
| 2018 |
Hardalo C, Lodise TP, Bidell M, Flanagan S, De Anda C, Anuskiewicz S, Prokocimer P. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. Expert Opinion On Drug Safety. 1-9. PMID 29528251 DOI: 10.1080/14740338.2018.1446939 |
0.345 |
|
| 2018 |
McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP. Effective Antimicrobial Stewardship Strategies for Cost-Effective Utilization of Telavancin for the Treatment of Patients With Hospital-Acquired Bacterial Pneumonia Caused by Staphylococcus aureus. Clinical Therapeutics. PMID 29454592 DOI: 10.1016/J.Clinthera.2018.01.010 |
0.43 |
|
| 2018 |
Echols R, Corvino F, Cai B, Lodise TP. 681. Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States Hospitals, 2010–2015 Open Forum Infectious Diseases. 5: S245-S246. DOI: 10.1093/ofid/ofy210.687 |
0.319 |
|
| 2018 |
Puzniak L, Fu R, Gundrum J, Lodise TP. 2414. Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated With Ceftolozane/Tazobactam Across 253 US Hospitals Open Forum Infectious Diseases. 5: S722-S722. DOI: 10.1093/Ofid/Ofy210.2067 |
0.382 |
|
| 2018 |
Saade E, Wilson B, Chakhtoura NGE, Viau R, Perez F, Lodise T, Bonomo RA. 2409. Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients Treated With Aztreonam and Ceftazidime Open Forum Infectious Diseases. 5: S720-S720. DOI: 10.1093/Ofid/Ofy210.2062 |
0.308 |
|
| 2018 |
Patel N, Clark J, Stornelli N, Belfiore G, Lodise TP. 1463. Comparative Evaluation of Adverse Tendon Events Between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin Among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia Open Forum Infectious Diseases. 5: S452-S453. DOI: 10.1093/Ofid/Ofy210.1293 |
0.577 |
|
| 2018 |
Lodise T, LaPensee K. 1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score Open Forum Infectious Diseases. 5: S452-S452. DOI: 10.1093/Ofid/Ofy210.1292 |
0.382 |
|
| 2018 |
Rank E, Lodise TP, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Lubowski T, Pearsall M, Carreno J. 1237. New York State Outpatient Regional Antibiogram for Urinary Pathogens: Have We Reached a Post Antibiotic Era for the Treatment of UTIs? Open Forum Infectious Diseases. 5: S376-S376. DOI: 10.1093/Ofid/Ofy210.1070 |
0.305 |
|
| 2018 |
Lodise TP, Echols R, Wang W, Corvino F, Cai B. 1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015 Open Forum Infectious Diseases. 5: S360-S360. DOI: 10.1093/Ofid/Ofy210.1024 |
0.413 |
|
| 2017 |
Lodise T, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB. Use of Pharmacokinetic and Pharmacodynamic Analyses to Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Serious Gram-Positive Infections. Antimicrobial Agents and Chemotherapy. PMID 29133566 DOI: 10.1128/Aac.01184-17 |
0.413 |
|
| 2017 |
Natesan S, Pai MP, Lodise TP. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. The Journal of Antimicrobial Chemotherapy. 72: 2813-2816. PMID 29091209 DOI: 10.1093/Jac/Dkx221 |
0.448 |
|
| 2017 |
Lodise TP, Fan W, Griffith DC, Dudley MN, Sulham KA. Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure: A Retrospective Cohort Analysis. Antimicrobial Agents and Chemotherapy. PMID 29038261 DOI: 10.1128/Aac.01165-17 |
0.318 |
|
| 2017 |
O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Miglis CM, Joshi M, Venkatesan N, Pais G, Cluff C, Lamar PC, Briyal S, Day JZ, Gulati A, Scheetz MH. 24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. Antimicrobial Agents and Chemotherapy. PMID 28807910 DOI: 10.1128/Aac.00416-17 |
0.312 |
|
| 2017 |
O'Donnell JN, Rhodes NJ, Miglis CM, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi M, Griffin B, Prozialeck W, Gulati A, Lodise TP, Scheetz MH. Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies. International Journal of Antimicrobial Agents. PMID 28803934 DOI: 10.1016/J.Ijantimicag.2017.08.012 |
0.357 |
|
| 2017 |
Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, Malik M, Mendes RE, Jones RN, McNutt LA, Lodise TP. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study. Bmc Infectious Diseases. 17: 534. PMID 28764660 DOI: 10.1186/S12879-017-2609-0 |
0.671 |
|
| 2017 |
Lodise T, Ye MJ, Zhao Q. Prevalence of Invasive Infections due to Carbapenem-Resistant Enterobacteriaceae Among Adult Patients Across US Hospitals. Antimicrobial Agents and Chemotherapy. PMID 28559271 DOI: 10.1128/Aac.00228-17 |
0.434 |
|
| 2017 |
Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials. Open Forum Infectious Diseases. 4: ofw274. PMID 28480266 DOI: 10.1093/Ofid/Ofw274 |
0.375 |
|
| 2017 |
Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Lodise TP. Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study. Diagnostic Microbiology and Infectious Disease. PMID 28449844 DOI: 10.1016/J.Diagmicrobio.2017.03.008 |
0.422 |
|
| 2017 |
Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, Corey GR, Lowy FD, Murray B, Miller LG, Holland TL. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 64: S24-S29. PMID 28350900 DOI: 10.1093/cid/ciw828 |
0.348 |
|
| 2017 |
Carreno JJ, Lomaestro B, Tietjan J, Lodise TP. Evaluation of a Bayesian Approach to Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling: A Pilot Study. Antimicrobial Agents and Chemotherapy. PMID 28289024 DOI: 10.1128/Aac.02478-16 |
0.344 |
|
| 2017 |
Bidell MR, Opraseuth MP, Yoon M, Mohr J, Lodise TP. Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections. Bmc Infectious Diseases. 17: 176. PMID 28241755 DOI: 10.1186/S12879-017-2270-7 |
0.457 |
|
| 2017 |
Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T. Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter? Open Forum Infectious Diseases. 4: S283-S284. DOI: 10.1093/Ofid/Ofx163.637 |
0.386 |
|
| 2017 |
Patel N, Clark J, Murray J, Bowles J, Lodise TP. Incidence and Predictors of Fluoroquinolone-Associated Adverse Tendon Events among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia Open Forum Infectious Diseases. 4: S584-S584. DOI: 10.1093/Ofid/Ofx163.1528 |
0.577 |
|
| 2017 |
Lodise TP, Rosenkranz SL, Finnemeyer M, Huvane J, Pereira A, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, et al. The Emperor’s New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE) Open Forum Infectious Diseases. 4. DOI: 10.1093/Ofid/Ofx162.074 |
0.431 |
|
| 2017 |
Lodise T, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Bonine NG. Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae? Open Forum Infectious Diseases. 4: S14-S14. DOI: 10.1093/Ofid/Ofx162.034 |
0.425 |
|
| 2016 |
Rahbar AJ, Lodise TP, Abraham P, Lockwood A, Pai MP, Patka J, Rabinovich M, Curzio K, Chester K, Williams B, Morse B, Chaar M, Huang V, Salomone J. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Surgical Infections. PMID 27841954 DOI: 10.1089/Sur.2015.113 |
0.409 |
|
| 2016 |
Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH. Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats. Antimicrobial Agents and Chemotherapy. PMID 27431226 DOI: 10.1128/Aac.00591-16 |
0.316 |
|
| 2016 |
Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, Cyr PL, Sulham KA. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. Journal of Managed Care & Specialty Pharmacy. 22: 752-764. PMID 27231802 DOI: 10.18553/Jmcp.2016.22.6.752 |
0.462 |
|
| 2016 |
Bidell MR, Lodise TP. Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? Pharmacotherapy. PMID 27138564 DOI: 10.1002/Phar.1761 |
0.392 |
|
| 2016 |
Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and Third-Generation Cephalosporin Resistance Among Hospitalized Patients with Urinary Tract Infections Due to Escherichia coli: Do Rates Vary by Hospital Characteristics and Geographic Region? Antimicrobial Agents and Chemotherapy. PMID 26926640 DOI: 10.1128/Aac.02505-15 |
0.419 |
|
| 2016 |
Berger A, Bhagnani T, Wang R, Zhao Q, Ye M, Lodise TP. Does Timing of Receipt of Appropriate Antimicrobial Therapy Make a Difference Among Patients With Serious Infections Due to Resistant Gram-Negative Pathogens? Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw194.154 |
0.439 |
|
| 2016 |
Lodise TP, Ye M, Keyloun KR, Zhao Q, Gillard P. Identification of Patients at Greatest Risk for Carbapenem Resistance in Patients With Serious Hospital-Onset Infections Due to Enterobacteriaceae Species Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw194.152 |
0.439 |
|
| 2016 |
McKinnell JA, Corman S, Patel D, Lodise TP. Telavancin Versus Vancomycin in the Treatment of Hospital-Acquired Pneumonia Caused by Staphylococcus aureus: Decision Analytic Model Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw172.953 |
0.357 |
|
| 2016 |
Lodise TP, Wang R, Bhagnani T, Zhao Q, Ye M, Berger A. Clinical and Economic Burden of Multi-drug Resistant Pseudomonas sp. (MDRP) Among Patients With Serious Infections in United States Hospitals Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw172.1593 |
0.414 |
|
| 2016 |
Natesan S, Pai MP, Lodise TP. Determination of Alternative Ceftolozane/Tazobactam (C/T) Dosing Regimens for Patients With Infections Due to Pseudomonas aeruginosa With High (C/T) MIC Values Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw172.1507 |
0.332 |
|
| 2016 |
Schriever C, Ahmed A, Delehanty K, Yager J, Farrow G, Kashtan R, Lodise T, Patel N. Comparison of Frequencies of Drug-Drug Interactions between Sofosbuvir/Ledipasvir and Ombitasvir/Dasabuvir/Paritaprevir/Ritonavir +/− Ribavirin among HIV/HCV Coinfected Patients Journal of Hepatology. 64: S801. DOI: 10.1016/S0168-8278(16)01563-4 |
0.438 |
|
| 2015 |
Martirosov DM, Lodise TP. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. PMID 27033631 DOI: 10.1016/J.Diagmicrobio.2015.10.008 |
0.409 |
|
| 2015 |
Lodise TP, Fan W, Sulham KA. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations. Clinical Therapeutics. PMID 26708118 DOI: 10.1016/J.Clinthera.2015.11.014 |
0.386 |
|
| 2015 |
Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, Sulham KA. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. Clinical Drug Investigation. PMID 26692006 DOI: 10.1007/S40261-015-0365-8 |
0.465 |
|
| 2015 |
Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, Bauer K, Goff DA, Adamson R, Leuthner K, Virata MD, McKinnell JA, Chaudhry SB, Eskandarian R, Lodise T, et al. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Clinical Therapeutics. PMID 26585355 DOI: 10.1016/J.Clinthera.2015.09.017 |
0.426 |
|
| 2015 |
Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. Bmc Infectious Diseases. 15: 503. PMID 26547411 DOI: 10.1186/S12879-015-1261-9 |
0.34 |
|
| 2015 |
Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis. Hospital Practice (1995). 43: 137-43. PMID 26224423 DOI: 10.1080/21548331.2015.1076325 |
0.394 |
|
| 2015 |
Culshaw D, Lamp KC, Yoon MJ, Lodise TP. Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease. PMID 26184127 DOI: 10.1016/J.Diagmicrobio.2015.06.003 |
0.44 |
|
| 2015 |
Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrobial Agents and Chemotherapy. 59: 2978-85. PMID 25753631 DOI: 10.1128/Aac.03970-14 |
0.456 |
|
| 2015 |
Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrobial Agents and Chemotherapy. 59: 1119-26. PMID 25487791 DOI: 10.1128/Aac.03643-14 |
0.395 |
|
| 2015 |
Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy. 59: 864-71. PMID 25421472 DOI: 10.1128/Aac.03688-14 |
0.424 |
|
| 2015 |
Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. The Journal of Antimicrobial Chemotherapy. 70: 877-81. PMID 25381169 DOI: 10.1093/Jac/Dku435 |
0.327 |
|
| 2015 |
Bhagnani T, Lodise T, Wang R, Bhurke S, Zhao Q, Berger A. Patterns of Empiric Antibiotic Therapy Among Hospitalized Patients With Complicated Intra-Abdominal Infections (cIAI) or Complicated Urinary Tract Infections (cUTI) due to Enterobacteriaceae Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.38 |
0.425 |
|
| 2015 |
Wang R, Lodise T, Bhagnani T, Zhao Q, Bhurke S, Berger A. Clinical and Economic Burden of Hospitalized Patients With Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.1385 |
0.448 |
|
| 2015 |
Lodise T, Ye M, Zhao Q. Relationship Between Cumulative Number of Prior Antibiotic Exposures and Carbapenem Resistance Among Patients With Hospital-Onset Infections due to Enterobacteriaceae spp Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.1343 |
0.47 |
|
| 2015 |
Mckinnell JA, Griffin M, Humphries R, Hindler J, Crowley O, Bedassie S, Stephenson K, Garland C, Lodise T. Distribution of Gram-Negative (GN) Pathogens and Carbapenem Resistance (CR) Patterns Across United States Hospitals: Will Klebsiella Become the New Pseudomonas? Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.1338 |
0.331 |
|
| 2014 |
LaPensee K, Fan W, Fiset C, Jiang H, Lodise TP. Efficacy and Hospitalization Length of Stay of Single Dose Oritavancin Compared to 7-10 Days of Vancomycin in Patients with Acute Bacterial Skin and Skin Structure Infections in the Us and Eastern Europe. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A664. PMID 27202424 DOI: 10.1016/J.Jval.2014.08.2445 |
0.415 |
|
| 2014 |
Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrobial Agents and Chemotherapy. 58: 7198-204. PMID 25246392 DOI: 10.1128/Aac.03509-14 |
0.411 |
|
| 2014 |
McConnell HL, Perris ET, Lowry C, Lodise T, Patel N. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infectious Diseases and Therapy. PMID 25245515 DOI: 10.1007/S40121-014-0041-Y |
0.555 |
|
| 2014 |
Carreno JJ, Lodise TP. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE. Infectious Diseases and Therapy. PMID 25193094 DOI: 10.1007/S40121-014-0036-8 |
0.445 |
|
| 2014 |
Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug Delivery Reviews. 77: 50-7. PMID 24910345 DOI: 10.1016/J.Addr.2014.05.016 |
0.422 |
|
| 2014 |
Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 666-75. PMID 24867791 DOI: 10.1093/Cid/Ciu398 |
0.651 |
|
| 2014 |
Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin . The Journal of Antimicrobial Chemotherapy. 69: 2547-55. PMID 24840624 DOI: 10.1093/Jac/Dku135 |
0.652 |
|
| 2014 |
Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrobial Agents and Chemotherapy. 58: 4094-102. PMID 24798288 DOI: 10.1128/Aac.02664-14 |
0.399 |
|
| 2014 |
Zasowski E, Butterfield JM, McNutt LA, Cohen J, Cosler L, Pai MP, Gottwald J, Chen WZ, Lodise TP. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Antimicrobial Agents and Chemotherapy. 58: 3804-13. PMID 24752270 DOI: 10.1128/Aac.02632-13 |
0.644 |
|
| 2014 |
Cardone KE, Chen WZ, Grabe DW, Batzold A, Manley HJ, Lodise TP. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis. The Journal of Antimicrobial Chemotherapy. 69: 1873-6. PMID 24722842 DOI: 10.1093/Jac/Dku081 |
0.374 |
|
| 2014 |
Puzniak LA, Capitano B, Biswas P, Lodise TP. Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: a pooled data analysis. Diagnostic Microbiology and Infectious Disease. 78: 295-301. PMID 24359932 DOI: 10.1016/J.Diagmicrobio.2013.11.001 |
0.431 |
|
| 2014 |
Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: S28-34. PMID 24343829 DOI: 10.1093/Cid/Cit615 |
0.414 |
|
| 2014 |
Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial Agents and Chemotherapy. 58: 309-16. PMID 24165176 DOI: 10.1128/Aac.01653-13 |
0.381 |
|
| 2014 |
Cardone KE, Grabe DW, Zasowski EJ, Lodise TP. Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy. 58: 19-26. PMID 24126585 DOI: 10.1128/Aac.00873-13 |
0.344 |
|
| 2014 |
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. The Journal of Antimicrobial Chemotherapy. 69: 176-9. PMID 23869050 DOI: 10.1093/Jac/Dkt300 |
0.38 |
|
| 2014 |
Mocarski M, Zhao Q, Ding M, Dixit S, Lodise T. 1041Economic Burden Associated with Key Gram-negative Pathogens among Patients with Complicated Urinary Tract Infections across US Hospitals Open Forum Infectious Diseases. 1: S305-S305. DOI: 10.1093/Ofid/Ofu052.749 |
0.427 |
|
| 2014 |
Mocarski M, Zhao Q, Ding M, Dixit S, Lodise T. 1031Comparative Epidemiology of Complicated Urinary Tract Infections (cUTI) by Age among US Hospitals Open Forum Infectious Diseases. 1: S302-S302. DOI: 10.1093/Ofid/Ofu052.739 |
0.363 |
|
| 2014 |
Moise P, Culshaw D, Wong-Beringer A, Bensman J, Lamp K, Smith WJ, Bauer K, Goff D, Adamson R, Leuthner K, Virata M, Mckinnell JA, Chaudhry SB, Eskandarian R, Lodise T, et al. 673Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation Open Forum Infectious Diseases. 1: S190-S190. DOI: 10.1093/Ofid/Ofu052.381 |
0.332 |
|
| 2014 |
Sulham K, LaPensee K, Fan W, Lodise T. Severity And Costs Of Acute Bacterial Skin And Skin Structure Infections By Treatment Setting: An Application Of The Eron Classification To A Real-World Database Value in Health. 17: A282. DOI: 10.1016/J.Jval.2014.03.1642 |
0.313 |
|
| 2013 |
Lodise TP, Patel N, Rivera A, Tristani L, Lazariu V, Vandewall H, McNutt LA. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrobial Agents and Chemotherapy. 57: 5901-11. PMID 24041888 DOI: 10.1128/Aac.00921-13 |
0.719 |
|
| 2013 |
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrobial Agents and Chemotherapy. 57: 5175-7. PMID 23896470 DOI: 10.1128/Aac.00539-13 |
0.36 |
|
| 2013 |
Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrobial Agents and Chemotherapy. PMID 23796929 DOI: 10.1128/Aac.00380-13 |
0.644 |
|
| 2013 |
Huang X, Beresford E, Lodise T, Friedland HD. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 70: 1057-64. PMID 23719884 DOI: 10.2146/Ajhp120438 |
0.375 |
|
| 2013 |
Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. The Annals of Pharmacotherapy. 47: 617-27. PMID 23585647 DOI: 10.1345/Aph.1R789 |
0.368 |
|
| 2013 |
Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis Antimicrobial Agents and Chemotherapy. 57: 864-872. PMID 23208714 DOI: 10.1128/Aac.02000-12 |
0.597 |
|
| 2013 |
Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter Antimicrobial Agents and Chemotherapy. 57: 734-744. PMID 23165462 DOI: 10.1128/Aac.01568-12 |
0.365 |
|
| 2013 |
Drusano GL, Lodise TP. Saving lives with optimal antimicrobial chemotherapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 245-7. PMID 23074312 DOI: 10.1093/Cid/Cis863 |
0.445 |
|
| 2013 |
Lodise T, Anzueto A, Shorr A, Weber D, Yang M, Smith A, Zhao Q, Huang X, File T. Retrospective Assessment of Time to Being Dischargeable From Hospital for Community Acquired Pneumonia (CAP) Using Data From the FOCUS Trials Chest. 144: 267A. DOI: 10.1378/Chest.1705024 |
0.318 |
|
| 2013 |
Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybaka MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate staphylococcus aureus bloodstream infection Antimicrobial Agents and Chemotherapy. 57: 4252-4259. DOI: 10.1128/AAC.00380-137 |
0.332 |
|
| 2012 |
Lodise TP, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs. 72: 1473-93. PMID 22779432 DOI: 10.2165/11635660-000000000-00000 |
0.438 |
|
| 2012 |
Stevens V, Lodise TP, Tsuji B, Stringham M, Butterfield J, Dodds Ashley E, Brown K, Forrest A, Brown J. The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia. Infection Control and Hospital Epidemiology. 33: 558-64. PMID 22561710 DOI: 10.1086/665731 |
0.424 |
|
| 2012 |
Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis Clinical Infectious Diseases. 54: 755-771. PMID 22302374 DOI: 10.1093/Cid/Cir935 |
0.443 |
|
| 2012 |
Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function Antimicrobial Agents and Chemotherapy. 56: 2062-2066. PMID 22252799 DOI: 10.1128/Aac.00383-11 |
0.375 |
|
| 2012 |
Patel N, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. The Journal of Antimicrobial Chemotherapy. 67: 727-35. PMID 22174041 DOI: 10.1093/Jac/Dkr522 |
0.58 |
|
| 2012 |
Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. The Journal of Antimicrobial Chemotherapy. 67: 494-502. PMID 22139199 DOI: 10.1093/Jac/Dkr467 |
0.388 |
|
| 2012 |
Cardone KE, Grabe DW, Kulawy RW, Daoui R, Roglieri J, Meola S, Drusano GL, Lodise TP. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy. 56: 725-30. PMID 22083473 DOI: 10.1128/Aac.05515-11 |
0.351 |
|
| 2012 |
Butterfield J, Lodise TP, Pai MP. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. Example of Antibiotic Therapy Management Therapeutic Drug Monitoring. 175-196. DOI: 10.1016/B978-0-12-385467-4.00009-9 |
0.314 |
|
| 2011 |
Kees MG, Lodise TP, Drusano GL. Determination of meropenem penetration into the lung from Sparse data. Antimicrobial Agents and Chemotherapy. 55: 5959-61. PMID 22081725 DOI: 10.1128/Aac.05066-11 |
0.371 |
|
| 2011 |
Butterfield JM, Tsuji BT, Brown J, Ashley ED, Hardy D, Brown K, Forrest A, Lodise TP. Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections. Antimicrobial Agents and Chemotherapy. 55: 5433-7. PMID 21930887 DOI: 10.1128/Aac.00407-11 |
0.483 |
|
| 2011 |
Pai MP, Lodise TP. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrobial Agents and Chemotherapy. 55: 5640-5. PMID 21930881 DOI: 10.1128/Aac.00422-11 |
0.308 |
|
| 2011 |
Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrobial Agents and Chemotherapy. 55: 5507-11. PMID 21911567 DOI: 10.1128/Aac.00712-11 |
0.324 |
|
| 2011 |
Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrobial Agents and Chemotherapy. 55: 4277-82. PMID 21670191 DOI: 10.1128/Aac.01674-10 |
0.542 |
|
| 2011 |
Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrobial Agents and Chemotherapy. 55: 3406-12. PMID 21576431 DOI: 10.1128/Aac.01559-10 |
0.37 |
|
| 2011 |
Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. The Journal of Antimicrobial Chemotherapy. 66: 1600-8. PMID 21508008 DOI: 10.1093/Jac/Dkr156 |
0.731 |
|
| 2011 |
Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 52: 969-74. PMID 21460308 DOI: 10.1093/Cid/Cir078 |
0.571 |
|
| 2011 |
Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, Drusano GL, Grabe DW. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clinical Journal of the American Society of Nephrology : Cjasn. 6: 1081-8. PMID 21393490 DOI: 10.2215/Cjn.08510910 |
0.589 |
|
| 2011 |
Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia Antimicrobial Agents and Chemotherapy. 55: 1606-1610. PMID 21300830 DOI: 10.1128/Aac.01330-10 |
0.413 |
|
| 2011 |
Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrobial Agents and Chemotherapy. 55: 1677-83. PMID 21282429 DOI: 10.1128/Aac.01224-10 |
0.588 |
|
| 2011 |
Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success. Journal of Hospital Medicine. 6: S16-23. PMID 21225946 DOI: 10.1002/Jhm.869 |
0.347 |
|
| 2011 |
Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Critical Care Clinics. 27: 1-18. PMID 21144983 DOI: 10.1016/J.Ccc.2010.11.003 |
0.375 |
|
| 2011 |
McKinnon P, Goff D, Boening A, Lodise T. PIN2 HEALTH OUTCOMES OF CLINICALLY RELEVANT PATIENT POPULATIONS TREATED WITH DAPTOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) SKIN INFECTIONS Value in Health. 14: A114. DOI: 10.1016/j.jval.2011.02.634 |
0.321 |
|
| 2010 |
Patel N, Scheetz MH, Drusano GL, Lodise TP. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. The Journal of Antimicrobial Chemotherapy. 65: 2285-90. PMID 20736235 DOI: 10.1093/Jac/Dkq323 |
0.572 |
|
| 2010 |
Bednarczyk RA, Nadeau JA, Davis CF, McCarthy A, Hussain S, Martiniano R, Lodise T, Zeolla MM, Coles FB, McNutt LA. Privacy in the pharmacy environment: analysis of observations from inside the pharmacy. Journal of the American Pharmacists Association : Japha. 50: 362-7. PMID 20452909 DOI: 10.1331/Japha.2010.09001 |
0.762 |
|
| 2010 |
Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients Antimicrobial Agents and Chemotherapy. 54: 460-465. PMID 19858253 DOI: 10.1128/Aac.00296-09 |
0.583 |
|
| 2009 |
Patel N, Lubanski P, Ferro S, Bonafede M, Harrington S, Evans A, Stellrecht K, Lodise TP. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus Antimicrobial Agents and Chemotherapy. 53: 5141-5144. PMID 19805558 DOI: 10.1128/Aac.00307-09 |
0.617 |
|
| 2009 |
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 49: 507-14. PMID 19586413 DOI: 10.1086/600884 |
0.637 |
|
| 2009 |
Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. American Journal of Therapeutics. 16: 508-11. PMID 19531934 DOI: 10.1097/Mjt.0B013E3181A1Afb7 |
0.614 |
|
| 2009 |
Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagnostic Microbiology and Infectious Disease. 64: 236-40. PMID 19500529 DOI: 10.1016/J.Diagmicrobio.2009.03.002 |
0.616 |
|
| 2009 |
Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrobial Agents and Chemotherapy. 53: 3294-301. PMID 19451287 DOI: 10.1128/Aac.00144-09 |
0.397 |
|
| 2009 |
Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. Management of meningitis due to antibiotic-resistant Acinetobacter species. The Lancet. Infectious Diseases. 9: 245-55. PMID 19324297 DOI: 10.1016/S1473-3099(09)70055-6 |
0.443 |
|
| 2008 |
Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. The Journal of Antimicrobial Chemotherapy. 62: 1138-41. PMID 18694905 DOI: 10.1093/Jac/Dkn329 |
0.433 |
|
| 2008 |
Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrobial Agents and Chemotherapy. 52: 3315-3320. PMID 18591266 DOI: 10.1128/Aac.00113-08 |
0.495 |
|
| 2008 |
Patel N, McNutt LA, Lodise TP. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 52: 2933-6. PMID 18519718 DOI: 10.1128/Aac.00456-08 |
0.722 |
|
| 2008 |
Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagnostic Microbiology and Infectious Disease. 61: 96-102. PMID 18384996 DOI: 10.1016/J.Diagmicrobio.2008.02.013 |
0.618 |
|
| 2008 |
Mohr JF, Peymann PJ, Troxell E, Lodise TP, Ostrosky-Zeichner L. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis. Clinical Therapeutics. 30: 152-7. PMID 18343251 DOI: 10.1016/J.Clinthera.2008.01.009 |
0.357 |
|
| 2008 |
Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial Agents and Chemotherapy. 52: 1330-6. PMID 18227177 DOI: 10.1128/Aac.01602-07 |
0.401 |
|
| 2008 |
Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrobial Agents and Chemotherapy. 52: 1945-51. PMID 17485507 DOI: 10.1128/Aac.00736-06 |
0.314 |
|
| 2007 |
Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy. 27: 1498-505. PMID 17963459 DOI: 10.1592/Phco.27.11.1498 |
0.359 |
|
| 2007 |
Bhat SV, Peleg AY, Lodise TP, Shutt KA, Capitano B, Potoski BA, Paterson DL. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrobial Agents and Chemotherapy. 51: 4390-5. PMID 17938179 DOI: 10.1128/Aac.01487-06 |
0.435 |
|
| 2007 |
Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy. 27: 1379-86. PMID 17896893 DOI: 10.1592/Phco.27.10.1379 |
0.314 |
|
| 2007 |
Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modelling and Monte Carlo simulation Journal of Antimicrobial Chemotherapy. 60: 1038-1044. PMID 17785282 DOI: 10.1093/Jac/Dkm325 |
0.395 |
|
| 2007 |
Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy. 51: 3977-82. PMID 17709460 DOI: 10.1128/Aac.00006-07 |
0.371 |
|
| 2007 |
Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 51: 3731-3. PMID 17664322 DOI: 10.1128/Aac.00101-07 |
0.419 |
|
| 2007 |
Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrobial Agents and Chemotherapy. 51: 3510-5. PMID 17646415 DOI: 10.1128/Aac.00338-07 |
0.607 |
|
| 2007 |
Lodise TP, Miller C, Patel N, Graves J, McNutt LA. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infection Control and Hospital Epidemiology. 28: 959-65. PMID 17620244 DOI: 10.1086/518972 |
0.75 |
|
| 2007 |
McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP, Miller RR, Furuno JP. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: 329-37. PMID 17599310 DOI: 10.1086/519283 |
0.373 |
|
| 2007 |
Lodise TP, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy. 27: 1001-12. PMID 17594206 DOI: 10.1592/Phco.27.7.1001 |
0.483 |
|
| 2007 |
Lodise TP, Nau R, Kinzig M, Jones RN, Drusano GL, Sörgel F. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 58: 445-52. PMID 17512154 DOI: 10.1016/J.Diagmicrobio.2007.03.015 |
0.355 |
|
| 2007 |
Lodise TP, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents and Chemotherapy. 51: 2378-87. PMID 17387149 DOI: 10.1128/Aac.01181-06 |
0.403 |
|
| 2007 |
LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrobial Agents and Chemotherapy. 51: 1315-20. PMID 17296740 DOI: 10.1128/Aac.00646-06 |
0.356 |
|
| 2007 |
Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 44: 357-63. PMID 17205441 DOI: 10.1086/510590 |
0.468 |
|
| 2007 |
Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrobial Agents and Chemotherapy. 51: 417-22. PMID 17158943 DOI: 10.1128/Aac.00851-06 |
0.672 |
|
| 2006 |
Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 26: 1320-32. PMID 16945055 DOI: 10.1592/Phco.26.9.1320 |
0.36 |
|
| 2006 |
Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagnostic Microbiology and Infectious Disease. 54: 223-30. PMID 16423490 DOI: 10.1016/J.Diagmicrobio.2005.09.007 |
0.31 |
|
| 2005 |
DeRyke CA, Lodise TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 128: 1414-22. PMID 16162737 DOI: 10.1378/Chest.128.3.1414 |
0.361 |
|
| 2005 |
Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease. 52: 113-22. PMID 15964499 DOI: 10.1016/J.Diagmicrobio.2005.02.007 |
0.477 |
|
| 2005 |
Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagnostic Microbiology and Infectious Disease. 52: 45-52. PMID 15878442 DOI: 10.1016/J.Diagmicrobio.2004.12.005 |
0.427 |
|
| 2004 |
Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrobial Agents and Chemotherapy. 48: 4718-24. PMID 15561849 DOI: 10.1128/Aac.48.12.4718-4724.2004 |
0.335 |
|
| 2004 |
Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. The Annals of Pharmacotherapy. 38: 1226-35. PMID 15187209 DOI: 10.1345/Aph.1E003 |
0.345 |
|
| 2003 |
Lodise TP, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infection Control and Hospital Epidemiology. 24: 655-61. PMID 14510247 DOI: 10.1086/502269 |
0.41 |
|
| 2003 |
Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 36: 1418-23. PMID 12766837 DOI: 10.1086/375057 |
0.406 |
|
| 2002 |
Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 34: 922-9. PMID 11880957 DOI: 10.1086/339211 |
0.327 |
|
| Show low-probability matches. |